Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Featured trial
Study to test asthama

To determine the etiology and clinical presentation of increased serum ammonia in infants and children presented to the Pediatric Genetic unit, Assiut University Hospital-To study the effects of certain precautions on serum ammonia levels.

Accepts healthy volunteers
  • 0 views
  • 17 Dec, 2024
  • 1 location
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in participants with mHSPC whose tumours are characterised by PTEN deficiency. The intention of the study is to demonstrate that in participants with mHSPC, the …

adenocarcinoma
luteinizing hormone-releasing hormone agonist
metastasis
antiandrogen therapy
prostate cancer
  • 0 views
  • 19 Feb, 2024
A Phase 1/2 Study of SHP648 an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

The purpose of this study is to evaluate the safety and dose escalation of SHP648 an adeno-associated viral vector for gene transfer in hemophilia B participants.

christmas disease
hemophilia
viral vector
prophylactic
gene therapy
  • 0 views
  • 19 Feb, 2024
Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

The primary objective of the trial is to evaluate the antitumor activity of atezolizumab and rucaparib in patients with selected advanced solid tumors as measured by the Overall Response Rate

fine-needle aspiration
formalin-fixed paraffin-embedded
measurable disease
metastasis
blood transfusion
  • 0 views
  • 19 Feb, 2024
Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype

This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-864 in PiZZ subjects.

  • 0 views
  • 19 Feb, 2024
Safety Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

Determine the safety, tolerability and pharmacokinetics of single doses of ARCT-810 in healthy adult subjects.

  • 0 views
  • 19 Feb, 2024
AAV Gene Therapy Study for Subjects With PKU

This is a Phase 1/2, open-label, dose escalation study to evaluate the safety, efficacy and tolerability of BMN 307 in adult PKU subjects with PAH deficiency. Participants will receive a single administration of BMN 307 and will be followed for safety and efficacy.

deficiency
gene therapy
  • 0 views
  • 19 Feb, 2024
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of …

deficiency
adrenaline
congenital adrenal hypoplasia
  • 0 views
  • 19 Feb, 2024
Gene Therapy for X Linked Severe Combined Immunodeficiency

A safety and efficacy clinical study of a lentiviral vector to transfer IL2RG complementary DNA to bone marrow stem cells in ten children with genetic diagnosed X-SCIDsevere combined immune deficiency .The ten children will be followed for 3-5 years and be evaluated by clinical characteristics, vector marking (vector copy number …

  • 0 views
  • 19 Feb, 2024
A Multinational Randomized Double-blind Placebo-controlled Study to Assess the Efficacy Pharmacodynamics Pharmacokinetics and Safety of Venglustat in Late-onset GM2

Primary Objectives: Primary population (adult participants with late-onset GM2 gangliosidosis): To assess the efficacy and pharmacodynamics (PD) of daily oral dosing of venglustat when administered over a 104-week period Secondary population (participants with juvenile/adolescent late-onset GM2 gangliosidosis, GM1 gangliosidosis, saposin C deficiency, sialidosis type 1 or juvenile/adult galactosialidosis): To assess …

  • 0 views
  • 19 Feb, 2024
  • 2 locations